UA117000C2 - Лікування раку tor-кіназними інгібіторами - Google Patents

Info

Publication number

UA117000C2

UA117000C2 UAA201504749A UAA201504749A UA117000C2 UA 117000 C2 UA117000 C2 UA 117000C2 UA A201504749 A UAA201504749 A UA A201504749A UA A201504749 A UAA201504749 A UA A201504749A UA 117000 C2 UA117000 C2 UA 117000C2

Authority

UA

Ukraine

Prior art keywords

substituted

compound

unsubstituted

prostate cancer

tok

Prior art date

2012-10-18

Links

• Espacenet
• Global Dossier
• Discuss

• 206010060862 Prostate cancer Diseases 0.000 title claims abstract description 124
• 208000000236 Prostatic Neoplasms Diseases 0.000 title claims abstract description 124
• 229940043355 kinase inhibitor Drugs 0.000 title claims description 366
• 239000003757 phosphotransferase inhibitor Substances 0.000 title claims description 366
• 238000011282 treatment Methods 0.000 title abstract description 44
• 238000000034 method Methods 0.000 claims abstract description 73
• 150000003839 salts Chemical class 0.000 claims abstract description 45
• 206010028980 Neoplasm Diseases 0.000 claims description 266
• 150000001875 compounds Chemical class 0.000 claims description 197
• 229940125904 compound 1 Drugs 0.000 claims description 123
• 230000005764 inhibitory process Effects 0.000 claims description 122
• 229940125782 compound 2 Drugs 0.000 claims description 107
• 229940068196 placebo Drugs 0.000 claims description 90
• 239000000902 placebo Substances 0.000 claims description 90
• 229960002930 sirolimus Drugs 0.000 claims description 70
• ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 67
• QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 67
• -1 dod Compound Chemical class 0.000 claims description 63
• 241000699670 Mus sp. Species 0.000 claims description 56
• 230000000694 effects Effects 0.000 claims description 42
• 238000004458 analytical method Methods 0.000 claims description 39
• 230000000259 anti-tumor effect Effects 0.000 claims description 38
• 230000037361 pathway Effects 0.000 claims description 34
• 210000004881 tumor cell Anatomy 0.000 claims description 31
• 239000000523 sample Substances 0.000 claims description 28
• 230000026731 phosphorylation Effects 0.000 claims description 26
• 238000006366 phosphorylation reaction Methods 0.000 claims description 26
• 239000012472 biological sample Substances 0.000 claims description 20
• 239000000090 biomarker Substances 0.000 claims description 18
• 230000002401 inhibitory effect Effects 0.000 claims description 17
• 238000011081 inoculation Methods 0.000 claims description 16
• 239000006166 lysate Substances 0.000 claims description 16
• 201000011510 cancer Diseases 0.000 claims description 12
• 238000011160 research Methods 0.000 claims description 11
• 230000027405 negative regulation of phosphorylation Effects 0.000 claims description 9
• 230000035772 mutation Effects 0.000 claims description 8
• 230000002018 overexpression Effects 0.000 claims description 8
• 102000005768 DNA-Activated Protein Kinase Human genes 0.000 claims description 7
• 108010006124 DNA-Activated Protein Kinase Proteins 0.000 claims description 7
• 239000000427 antigen Substances 0.000 claims description 5
• 108091007433 antigens Proteins 0.000 claims description 5
• 102000036639 antigens Human genes 0.000 claims description 5
• 239000002552 dosage form Substances 0.000 claims description 5
• 210000002307 prostate Anatomy 0.000 claims description 5
• 238000005070 sampling Methods 0.000 claims description 5
• 235000010443 alginic acid Nutrition 0.000 claims description 4
• 239000000499 gel Substances 0.000 claims description 3
• 239000000783 alginic acid Substances 0.000 claims description 2
• 229910052740 iodine Inorganic materials 0.000 claims description 2
• 210000003462 vein Anatomy 0.000 claims 2
• 244000099147 Ananas comosus Species 0.000 claims 1
• 235000007119 Ananas comosus Nutrition 0.000 claims 1
• 101100123850 Caenorhabditis elegans her-1 gene Proteins 0.000 claims 1
• 244000068988 Glycine max Species 0.000 claims 1
• 235000010469 Glycine max Nutrition 0.000 claims 1
• 244000130592 Hibiscus syriacus Species 0.000 claims 1
• 235000018081 Hibiscus syriacus Nutrition 0.000 claims 1
• 101100481787 Mus musculus Tob1 gene Proteins 0.000 claims 1
• 241000492700 Novenia Species 0.000 claims 1
• 101150034459 Parpbp gene Proteins 0.000 claims 1
• 241000233679 Peronosporaceae Species 0.000 claims 1
• 241000549435 Pria Species 0.000 claims 1
• 241000220317 Rosa Species 0.000 claims 1
• 241000159610 Roya <green alga> Species 0.000 claims 1
• 244000269722 Thea sinensis Species 0.000 claims 1
• 210000004556 brain Anatomy 0.000 claims 1
• 239000010445 mica Substances 0.000 claims 1
• 229910052618 mica group Inorganic materials 0.000 claims 1
• HUTNOYOBQPAKIA-UHFFFAOYSA-N 1h-pyrazin-2-one Chemical compound OC1=CN=CC=N1 HUTNOYOBQPAKIA-UHFFFAOYSA-N 0.000 abstract description 34
• 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 abstract 1
• 239000003112 inhibitor Substances 0.000 description 202
• 125000003118 aryl group Chemical group 0.000 description 124
• 210000004027 cell Anatomy 0.000 description 117
• 125000000753 cycloalkyl group Chemical group 0.000 description 99
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 80
• 125000004415 heterocyclylalkyl group Chemical group 0.000 description 78
• 125000001072 heteroaryl group Chemical group 0.000 description 77
• 125000000217 alkyl group Chemical group 0.000 description 67
• 239000003826 tablet Substances 0.000 description 42
• 241001465754 Metazoa Species 0.000 description 40
• 230000037396 body weight Effects 0.000 description 36
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 36
• 125000001424 substituent group Chemical group 0.000 description 33
• 125000000623 heterocyclic group Chemical group 0.000 description 32
• 239000000758 substrate Substances 0.000 description 32
• 239000000203 mixture Substances 0.000 description 28
• AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 24
• 239000000243 solution Substances 0.000 description 24
• 238000003556 assay Methods 0.000 description 23
• 229910052736 halogen Inorganic materials 0.000 description 23
• 150000002367 halogens Chemical class 0.000 description 23
• 239000000651 prodrug Substances 0.000 description 23
• 229940002612 prodrug Drugs 0.000 description 23
• 125000003107 substituted aryl group Chemical group 0.000 description 23
• 108091000080 Phosphotransferase Proteins 0.000 description 22
• KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 22
• 102000020233 phosphotransferase Human genes 0.000 description 22
• 239000013641 positive control Substances 0.000 description 21
• 239000012453 solvate Substances 0.000 description 21
• 102000001253 Protein Kinase Human genes 0.000 description 19
• 238000003364 immunohistochemistry Methods 0.000 description 19
• 108060006633 protein kinase Proteins 0.000 description 19
• 125000004076 pyridyl group Chemical group 0.000 description 19
• 230000004614 tumor growth Effects 0.000 description 19
• 125000004093 cyano group Chemical group *C#N 0.000 description 18
• JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 18
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 18
• 150000003222 pyridines Chemical class 0.000 description 18
• 230000004663 cell proliferation Effects 0.000 description 17
• 230000036470 plasma concentration Effects 0.000 description 17
• 108090000623 proteins and genes Proteins 0.000 description 17
• 102000004169 proteins and genes Human genes 0.000 description 17
• 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 17
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 16
• 125000003545 alkoxy group Chemical group 0.000 description 16
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
• 230000009036 growth inhibition Effects 0.000 description 16
• 238000011534 incubation Methods 0.000 description 16
• 210000001519 tissue Anatomy 0.000 description 16
• JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 15
• 239000003814 drug Substances 0.000 description 15
• 238000002474 experimental method Methods 0.000 description 15
• 238000005406 washing Methods 0.000 description 15
• SMWDFEZZVXVKRB-UHFFFAOYSA-N anhydrous quinoline Natural products N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 14
• 230000006907 apoptotic process Effects 0.000 description 14
• 125000004429 atom Chemical group 0.000 description 14
• SIKJAQJRHWYJAI-UHFFFAOYSA-N benzopyrrole Natural products C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 14
• 238000001514 detection method Methods 0.000 description 14
• 201000010099 disease Diseases 0.000 description 14
• PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 14
• RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 14
• 150000002475 indoles Chemical class 0.000 description 14
• 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 13
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 13
• 229940079593 drug Drugs 0.000 description 13
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 13
• 239000001963 growth medium Substances 0.000 description 13
• 238000005259 measurement Methods 0.000 description 13
• 125000001624 naphthyl group Chemical group 0.000 description 13
• 239000002953 phosphate buffered saline Substances 0.000 description 13
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
• 239000000872 buffer Substances 0.000 description 12
• 125000004432 carbon atom Chemical group C* 0.000 description 12
• 231100000673 dose–response relationship Toxicity 0.000 description 12
• 230000009467 reduction Effects 0.000 description 12
• 208000011581 secondary neoplasm Diseases 0.000 description 12
• 239000011534 wash buffer Substances 0.000 description 12
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
• PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 11
• 230000000903 blocking effect Effects 0.000 description 11
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 11
• 239000007788 liquid Substances 0.000 description 11
• 150000003254 radicals Chemical group 0.000 description 11
• 238000012360 testing method Methods 0.000 description 11
• 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 10
• 230000008859 change Effects 0.000 description 10
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 10
• 230000001404 mediated effect Effects 0.000 description 10
• 239000002609 medium Substances 0.000 description 10
• 230000004044 response Effects 0.000 description 10
• 239000000725 suspension Substances 0.000 description 10
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 9
• QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
• 230000001028 anti-proliverative effect Effects 0.000 description 9
• 239000002775 capsule Substances 0.000 description 9
• 230000022131 cell cycle Effects 0.000 description 9
• 239000013592 cell lysate Substances 0.000 description 9
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 9
• 238000010790 dilution Methods 0.000 description 9
• 239000012895 dilution Substances 0.000 description 9
• 230000012010 growth Effects 0.000 description 9
• 125000002768 hydroxyalkyl group Chemical group 0.000 description 9
• 239000003550 marker Substances 0.000 description 9
• 239000012528 membrane Substances 0.000 description 9
• 230000002062 proliferating effect Effects 0.000 description 9
• 125000003226 pyrazolyl group Chemical group 0.000 description 9
• 150000003230 pyrimidines Chemical class 0.000 description 9
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
• YTPLMLYBLZKORZ-UHFFFAOYSA-N Divinylene sulfide Natural products C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 8
• 230000001772 anti-angiogenic effect Effects 0.000 description 8
• 239000008280 blood Substances 0.000 description 8
• 229910052799 carbon Inorganic materials 0.000 description 8
• 238000011161 development Methods 0.000 description 8
• 230000018109 developmental process Effects 0.000 description 8
• 230000010534 mechanism of action Effects 0.000 description 8
• 229910052757 nitrogen Inorganic materials 0.000 description 8
• 235000020079 raki Nutrition 0.000 description 8
• 229930192474 thiophene Natural products 0.000 description 8
• 150000003577 thiophenes Chemical class 0.000 description 8
• 230000003442 weekly effect Effects 0.000 description 8
• KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 7
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 7
• 229920002472 Starch Polymers 0.000 description 7
• 230000001640 apoptogenic effect Effects 0.000 description 7
• 125000003710 aryl alkyl group Chemical group 0.000 description 7
• 239000011324 bead Substances 0.000 description 7
• 238000001574 biopsy Methods 0.000 description 7
• 239000003153 chemical reaction reagent Substances 0.000 description 7
• 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 7
• 230000003111 delayed effect Effects 0.000 description 7
• 239000003085 diluting agent Substances 0.000 description 7
• 239000011737 fluorine Substances 0.000 description 7
• 229910052731 fluorine Inorganic materials 0.000 description 7
• 125000005842 heteroatom Chemical group 0.000 description 7
• 238000007912 intraperitoneal administration Methods 0.000 description 7
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 7
• 238000011002 quantification Methods 0.000 description 7
• 235000019698 starch Nutrition 0.000 description 7
• 208000024891 symptom Diseases 0.000 description 7
• 125000001425 triazolyl group Chemical group 0.000 description 7
• DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 6
• 241000283707 Capra Species 0.000 description 6
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 6
• 210000004369 blood Anatomy 0.000 description 6
• 210000004204 blood vessel Anatomy 0.000 description 6
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
• 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 6
• ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 6
• 229910052739 hydrogen Inorganic materials 0.000 description 6
• 230000000155 isotopic effect Effects 0.000 description 6
• 108010082117 matrigel Proteins 0.000 description 6
• 239000008194 pharmaceutical composition Substances 0.000 description 6
• 125000000714 pyrimidinyl group Chemical group 0.000 description 6
• 230000002829 reductive effect Effects 0.000 description 6
• 229920006395 saturated elastomer Polymers 0.000 description 6
• 239000008107 starch Substances 0.000 description 6
• 239000000126 substance Substances 0.000 description 6
• 102100022466 Eukaryotic translation initiation factor 4E-binding protein 1 Human genes 0.000 description 5
• 108050000946 Eukaryotic translation initiation factor 4E-binding protein 1 Proteins 0.000 description 5
• 108010089430 Phosphoproteins Proteins 0.000 description 5
• 102000007982 Phosphoproteins Human genes 0.000 description 5
• 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 5
• 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 5
• 230000033115 angiogenesis Effects 0.000 description 5
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
• 238000001516 cell proliferation assay Methods 0.000 description 5
• 230000001413 cellular effect Effects 0.000 description 5
• 125000004122 cyclic group Chemical group 0.000 description 5
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 5
• 238000009826 distribution Methods 0.000 description 5
• 125000001188 haloalkyl group Chemical group 0.000 description 5
• 125000002883 imidazolyl group Chemical group 0.000 description 5
• 230000001965 increasing effect Effects 0.000 description 5
• 125000001041 indolyl group Chemical group 0.000 description 5
• 238000002372 labelling Methods 0.000 description 5
• 230000003285 pharmacodynamic effect Effects 0.000 description 5
• 150000003053 piperidines Chemical class 0.000 description 5
• 230000002265 prevention Effects 0.000 description 5
• 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 5
• 239000000829 suppository Substances 0.000 description 5
• 238000001356 surgical procedure Methods 0.000 description 5
• NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 5
• 125000003831 tetrazolyl group Chemical group 0.000 description 5
• 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 4
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 4
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
• 231100001074 DNA strand break Toxicity 0.000 description 4
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
• ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 4
• 101000679555 Homo sapiens TOX high mobility group box family member 2 Proteins 0.000 description 4
• OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
• 229930195725 Mannitol Natural products 0.000 description 4
• 229930040373 Paraformaldehyde Natural products 0.000 description 4
• XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 4
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
• 102100022611 TOX high mobility group box family member 2 Human genes 0.000 description 4
• 125000003342 alkenyl group Chemical group 0.000 description 4
• 125000004104 aryloxy group Chemical group 0.000 description 4
• 239000011230 binding agent Substances 0.000 description 4
• 239000004202 carbamide Substances 0.000 description 4
• 239000006285 cell suspension Substances 0.000 description 4
• 239000001913 cellulose Substances 0.000 description 4
• 235000010980 cellulose Nutrition 0.000 description 4
• 229920002678 cellulose Polymers 0.000 description 4
• 239000003795 chemical substances by application Substances 0.000 description 4
• 230000000875 corresponding effect Effects 0.000 description 4
• 206010012601 diabetes mellitus Diseases 0.000 description 4
• 238000007865 diluting Methods 0.000 description 4
• 230000014509 gene expression Effects 0.000 description 4
• 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 4
• 230000003834 intracellular effect Effects 0.000 description 4
• 239000000314 lubricant Substances 0.000 description 4
• 239000012139 lysis buffer Substances 0.000 description 4
• 239000000594 mannitol Substances 0.000 description 4
• 235000010355 mannitol Nutrition 0.000 description 4
• 229920000609 methyl cellulose Polymers 0.000 description 4
• 235000010981 methylcellulose Nutrition 0.000 description 4
• 239000001923 methylcellulose Substances 0.000 description 4
• 125000002950 monocyclic group Chemical group 0.000 description 4
• 239000013642 negative control Substances 0.000 description 4
• 229920002866 paraformaldehyde Polymers 0.000 description 4
• 125000004193 piperazinyl group Chemical group 0.000 description 4
• 125000005936 piperidyl group Chemical group 0.000 description 4
• 229920001223 polyethylene glycol Polymers 0.000 description 4
• 239000000843 powder Substances 0.000 description 4
• XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 4
• 208000023958 prostate neoplasm Diseases 0.000 description 4
• 125000000168 pyrrolyl group Chemical group 0.000 description 4
• 238000001959 radiotherapy Methods 0.000 description 4
• 238000010186 staining Methods 0.000 description 4
• 239000011550 stock solution Substances 0.000 description 4
• 235000000346 sugar Nutrition 0.000 description 4
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
• OKTJSMMVPCPJKN-OUBTZVSYSA-N Carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 description 3
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
• 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 3
• 102000004190 Enzymes Human genes 0.000 description 3
• 108090000790 Enzymes Proteins 0.000 description 3
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
• 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 3
• 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 3
• 239000002202 Polyethylene glycol Substances 0.000 description 3
• 229930006000 Sucrose Natural products 0.000 description 3
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
• 238000002835 absorbance Methods 0.000 description 3
• 239000002253 acid Substances 0.000 description 3
• 230000004913 activation Effects 0.000 description 3
• 125000004442 acylamino group Chemical group 0.000 description 3
• 229920000615 alginic acid Polymers 0.000 description 3
• 125000004183 alkoxy alkyl group Chemical group 0.000 description 3
• 125000003282 alkyl amino group Chemical group 0.000 description 3
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
• 230000033228 biological regulation Effects 0.000 description 3
• 235000010290 biphenyl Nutrition 0.000 description 3
• 239000004305 biphenyl Substances 0.000 description 3
• 238000010241 blood sampling Methods 0.000 description 3
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
• 229910052794 bromium Inorganic materials 0.000 description 3
• 239000001506 calcium phosphate Substances 0.000 description 3
• 235000011010 calcium phosphates Nutrition 0.000 description 3
• 238000005119 centrifugation Methods 0.000 description 3
• 239000000460 chlorine Substances 0.000 description 3
• 229910052801 chlorine Inorganic materials 0.000 description 3
• 230000002596 correlated effect Effects 0.000 description 3
• 238000004090 dissolution Methods 0.000 description 3
• 239000003937 drug carrier Substances 0.000 description 3
• 238000005516 engineering process Methods 0.000 description 3
• 125000002541 furyl group Chemical group 0.000 description 3
• 150000002431 hydrogen Chemical class 0.000 description 3
• 239000001257 hydrogen Substances 0.000 description 3
• 230000006872 improvement Effects 0.000 description 3
• 239000007924 injection Substances 0.000 description 3
• 238000002347 injection Methods 0.000 description 3
• 230000003993 interaction Effects 0.000 description 3
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
• 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 3
• 125000000842 isoxazolyl group Chemical group 0.000 description 3
• 239000008101 lactose Substances 0.000 description 3
• 210000003141 lower extremity Anatomy 0.000 description 3
• 230000002934 lysing effect Effects 0.000 description 3
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 3
• 238000012423 maintenance Methods 0.000 description 3
• 230000003211 malignant effect Effects 0.000 description 3
• 229910052751 metal Inorganic materials 0.000 description 3
• 239000002184 metal Substances 0.000 description 3
• 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 3
• 238000012544 monitoring process Methods 0.000 description 3
• 231100000252 nontoxic Toxicity 0.000 description 3
• 230000003000 nontoxic effect Effects 0.000 description 3
• 239000002773 nucleotide Substances 0.000 description 3
• 125000003729 nucleotide group Chemical group 0.000 description 3
• 125000002971 oxazolyl group Chemical group 0.000 description 3
• 239000000546 pharmaceutical excipient Substances 0.000 description 3
• 238000002360 preparation method Methods 0.000 description 3
• 230000035755 proliferation Effects 0.000 description 3
• 125000006413 ring segment Chemical group 0.000 description 3
• 210000002966 serum Anatomy 0.000 description 3
• 230000008054 signal transmission Effects 0.000 description 3
• 238000007390 skin biopsy Methods 0.000 description 3
• 239000001509 sodium citrate Substances 0.000 description 3
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
• 239000005720 sucrose Substances 0.000 description 3
• 239000000454 talc Substances 0.000 description 3
• 229910052623 talc Inorganic materials 0.000 description 3
• 235000012222 talc Nutrition 0.000 description 3
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
• 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 3
• 125000001412 tetrahydropyranyl group Chemical group 0.000 description 3
• 125000000335 thiazolyl group Chemical group 0.000 description 3
• 125000001544 thienyl group Chemical group 0.000 description 3
• 230000036962 time dependent Effects 0.000 description 3
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
• 229920002554 vinyl polymer Polymers 0.000 description 3
• 239000001993 wax Substances 0.000 description 3
• 239000012224 working solution Substances 0.000 description 3
• 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 2
• YMTNFIVNOUHQSD-UHFFFAOYSA-N 2-(4-cyanophenyl)-8-oxo-9-phenyl-7h-purine-6-carboxamide Chemical compound O=C1NC=2C(C(=O)N)=NC(C=3C=CC(=CC=3)C#N)=NC=2N1C1=CC=CC=C1 YMTNFIVNOUHQSD-UHFFFAOYSA-N 0.000 description 2
• VVBJUWBGVSHSFS-UHFFFAOYSA-N 2-(4-nitrophenyl)-8-oxo-9-phenyl-7h-purine-6-carboxamide Chemical compound O=C1NC=2C(C(=O)N)=NC(C=3C=CC(=CC=3)[N+]([O-])=O)=NC=2N1C1=CC=CC=C1 VVBJUWBGVSHSFS-UHFFFAOYSA-N 0.000 description 2
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
• VTSCFUAJBOFZEI-UHFFFAOYSA-N 8-oxo-9-phenyl-2-pyridin-3-yl-7h-purine-6-carboxamide Chemical compound O=C1NC=2C(C(=O)N)=NC(C=3C=NC=CC=3)=NC=2N1C1=CC=CC=C1 VTSCFUAJBOFZEI-UHFFFAOYSA-N 0.000 description 2
• DXHKTHGKGVIGTC-UHFFFAOYSA-N 9-(2-hydroxyethyl)-2-(trifluoromethyl)purine-6-carboxamide Chemical compound NC(=O)C1=NC(C(F)(F)F)=NC2=C1N=CN2CCO DXHKTHGKGVIGTC-UHFFFAOYSA-N 0.000 description 2
• MWKDGWKQVQCNGG-UHFFFAOYSA-N 9-(2-hydroxyethyl)-2-phenylpurine-6-carboxamide Chemical compound N=1C=2N(CCO)C=NC=2C(C(=O)N)=NC=1C1=CC=CC=C1 MWKDGWKQVQCNGG-UHFFFAOYSA-N 0.000 description 2
• GNCVUNHMILWMNF-UHFFFAOYSA-N 9-benzyl-2-(4-methoxyphenyl)-8-oxo-7h-purine-6-carboxamide Chemical compound C1=CC(OC)=CC=C1C1=NC(C(N)=O)=C(NC(=O)N2CC=3C=CC=CC=3)C2=N1 GNCVUNHMILWMNF-UHFFFAOYSA-N 0.000 description 2
• QEVNUSASORPKFA-UHFFFAOYSA-N 9-benzyl-2-methylpurine-6-carboxamide Chemical compound C12=NC(C)=NC(C(N)=O)=C2N=CN1CC1=CC=CC=C1 QEVNUSASORPKFA-UHFFFAOYSA-N 0.000 description 2
• 244000215068 Acacia senegal Species 0.000 description 2
• QGZKDVFQNNGYKY-OUBTZVSYSA-N Ammonia-15N Chemical compound [15NH3] QGZKDVFQNNGYKY-OUBTZVSYSA-N 0.000 description 2
• 206010003497 Asphyxia Diseases 0.000 description 2
• 206010003571 Astrocytoma Diseases 0.000 description 2
• 206010065869 Astrocytoma, low grade Diseases 0.000 description 2
• 102000004506 Blood Proteins Human genes 0.000 description 2
• 108010017384 Blood Proteins Proteins 0.000 description 2
• 208000031648 Body Weight Changes Diseases 0.000 description 2
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
• VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
• 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 2
• YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
• 206010061818 Disease progression Diseases 0.000 description 2
• JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 2
• HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 2
• 229930091371 Fructose Natural products 0.000 description 2
• 239000005715 Fructose Substances 0.000 description 2
• RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
• 108010010803 Gelatin Proteins 0.000 description 2
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
• 229920000084 Gum arabic Polymers 0.000 description 2
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
• CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
• AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
• PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
• CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 2
• 102000019040 Nuclear Antigens Human genes 0.000 description 2
• 108010051791 Nuclear Antigens Proteins 0.000 description 2
• LWYDBGXNFDMNFN-XYPYZODXSA-N O=C1NC=2C(C(=O)N)=NC(C=3C=C(O)C=CC=3)=NC=2N1[C@H]1CC[C@H](O)CC1 Chemical compound O=C1NC=2C(C(=O)N)=NC(C=3C=C(O)C=CC=3)=NC=2N1[C@H]1CC[C@H](O)CC1 LWYDBGXNFDMNFN-XYPYZODXSA-N 0.000 description 2
• SHLJSRZKHPHFBY-XYPYZODXSA-N O=C1NC=2C(C(=O)N)=NC(C=3C=NC=CC=3)=NC=2N1[C@H]1CC[C@H](O)CC1 Chemical compound O=C1NC=2C(C(=O)N)=NC(C=3C=NC=CC=3)=NC=2N1[C@H]1CC[C@H](O)CC1 SHLJSRZKHPHFBY-XYPYZODXSA-N 0.000 description 2
• 108091005804 Peptidases Proteins 0.000 description 2
• 239000004793 Polystyrene Substances 0.000 description 2
• 102000007066 Prostate-Specific Antigen Human genes 0.000 description 2
• 108010072866 Prostate-Specific Antigen Proteins 0.000 description 2
• 239000004365 Protease Substances 0.000 description 2
• 208000006265 Renal cell carcinoma Diseases 0.000 description 2
• 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
• CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 2
• ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 2
• 235000010489 acacia gum Nutrition 0.000 description 2
• 239000000205 acacia gum Substances 0.000 description 2
• 150000007513 acids Chemical class 0.000 description 2
• 150000001299 aldehydes Chemical class 0.000 description 2
• 125000005262 alkoxyamine group Chemical group 0.000 description 2
• 150000001409 amidines Chemical class 0.000 description 2
• 238000011319 anticancer therapy Methods 0.000 description 2
• 239000007864 aqueous solution Substances 0.000 description 2
• 150000001540 azides Chemical class 0.000 description 2
• 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
• 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
• 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 2
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
• 210000000601 blood cell Anatomy 0.000 description 2
• 230000004579 body weight change Effects 0.000 description 2
• 229910000389 calcium phosphate Inorganic materials 0.000 description 2
• 150000003857 carboxamides Chemical class 0.000 description 2
• 239000001768 carboxy methyl cellulose Substances 0.000 description 2
• 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
• 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
• 230000006037 cell lysis Effects 0.000 description 2
• 230000033077 cellular process Effects 0.000 description 2
• 238000006243 chemical reaction Methods 0.000 description 2
• 239000007910 chewable tablet Substances 0.000 description 2
• 229940125898 compound 5 Drugs 0.000 description 2
• 239000013078 crystal Substances 0.000 description 2
• XLJMAIOERFSOGZ-UHFFFAOYSA-M cyanate Chemical compound [O-]C#N XLJMAIOERFSOGZ-UHFFFAOYSA-M 0.000 description 2
• JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 2
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
• 230000034994 death Effects 0.000 description 2
• 238000004042 decolorization Methods 0.000 description 2
• 230000003247 decreasing effect Effects 0.000 description 2
• 230000001419 dependent effect Effects 0.000 description 2
• 229910052805 deuterium Inorganic materials 0.000 description 2
• SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 2
• 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 2
• 230000005750 disease progression Effects 0.000 description 2
• 208000035475 disorder Diseases 0.000 description 2
• 230000009977 dual effect Effects 0.000 description 2
• 150000002081 enamines Chemical class 0.000 description 2
• 210000002889 endothelial cell Anatomy 0.000 description 2
• 238000011067 equilibration Methods 0.000 description 2
• 150000002148 esters Chemical class 0.000 description 2
• 229960005167 everolimus Drugs 0.000 description 2
• 239000011536 extraction buffer Substances 0.000 description 2
• 239000012091 fetal bovine serum Substances 0.000 description 2
• 235000013305 food Nutrition 0.000 description 2
• 125000000524 functional group Chemical group 0.000 description 2
• 239000008273 gelatin Substances 0.000 description 2
• 229920000159 gelatin Polymers 0.000 description 2
• 235000019322 gelatine Nutrition 0.000 description 2
• 235000011852 gelatine desserts Nutrition 0.000 description 2
• 239000008103 glucose Substances 0.000 description 2
• 239000008187 granular material Substances 0.000 description 2
• 230000009422 growth inhibiting effect Effects 0.000 description 2
• 229960002897 heparin Drugs 0.000 description 2
• 229920000669 heparin Polymers 0.000 description 2
• 150000007857 hydrazones Chemical class 0.000 description 2
• ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 2
• 125000002632 imidazolidinyl group Chemical group 0.000 description 2
• 125000002636 imidazolinyl group Chemical group 0.000 description 2
• 150000003949 imides Chemical class 0.000 description 2
• 238000003018 immunoassay Methods 0.000 description 2
• 238000010166 immunofluorescence Methods 0.000 description 2
• 230000002055 immunohistochemical effect Effects 0.000 description 2
• 230000001771 impaired effect Effects 0.000 description 2
• 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 2
• 230000001939 inductive effect Effects 0.000 description 2
• 239000007928 intraperitoneal injection Substances 0.000 description 2
• PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
• 239000012948 isocyanate Substances 0.000 description 2
• 150000002513 isocyanates Chemical class 0.000 description 2
• 229960002725 isoflurane Drugs 0.000 description 2
• 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
• 150000002540 isothiocyanates Chemical class 0.000 description 2
• 150000002576 ketones Chemical class 0.000 description 2
• 239000007937 lozenge Substances 0.000 description 2
• 229910052749 magnesium Inorganic materials 0.000 description 2
• 235000019359 magnesium stearate Nutrition 0.000 description 2
• 230000007246 mechanism Effects 0.000 description 2
• 230000002503 metabolic effect Effects 0.000 description 2
• 230000004060 metabolic process Effects 0.000 description 2
• LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
• 230000002906 microbiologic effect Effects 0.000 description 2
• 210000004088 microvessel Anatomy 0.000 description 2
• 150000007522 mineralic acids Chemical class 0.000 description 2
• 125000002757 morpholinyl group Chemical group 0.000 description 2
• 239000004570 mortar (masonry) Substances 0.000 description 2
• VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical class N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
• 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
• 238000003305 oral gavage Methods 0.000 description 2
• 150000007524 organic acids Chemical class 0.000 description 2
• 150000002923 oximes Chemical class 0.000 description 2
• 239000001301 oxygen Substances 0.000 description 2
• 229910052760 oxygen Inorganic materials 0.000 description 2
• 238000007911 parenteral administration Methods 0.000 description 2
• 239000008188 pellet Substances 0.000 description 2
• 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
• 239000012071 phase Substances 0.000 description 2
• 125000000394 phosphonato group Chemical group [O-]P([O-])(*)=O 0.000 description 2
• 229910000073 phosphorus hydride Inorganic materials 0.000 description 2
• 238000002616 plasmapheresis Methods 0.000 description 2
• 125000003367 polycyclic group Chemical group 0.000 description 2
• 229940068918 polyethylene glycol 400 Drugs 0.000 description 2
• 229920002223 polystyrene Polymers 0.000 description 2
• 230000003389 potentiating effect Effects 0.000 description 2
• 230000008569 process Effects 0.000 description 2
• 108090000765 processed proteins & peptides Proteins 0.000 description 2
• 238000012545 processing Methods 0.000 description 2
• QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
• 230000009822 protein phosphorylation Effects 0.000 description 2
• 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 2
• 125000003373 pyrazinyl group Chemical group 0.000 description 2
• 125000002098 pyridazinyl group Chemical group 0.000 description 2
• UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 2
• 230000002285 radioactive effect Effects 0.000 description 2
• 238000002271 resection Methods 0.000 description 2
• 102220125116 rs867314622 Human genes 0.000 description 2
• 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
• 208000037921 secondary disease Diseases 0.000 description 2
• 238000000926 separation method Methods 0.000 description 2
• 235000017557 sodium bicarbonate Nutrition 0.000 description 2
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
• 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
• 239000007787 solid Substances 0.000 description 2
• 239000002904 solvent Substances 0.000 description 2
• 239000012128 staining reagent Substances 0.000 description 2
• 238000011301 standard therapy Methods 0.000 description 2
• 238000003756 stirring Methods 0.000 description 2
• 201000004059 subependymal giant cell astrocytoma Diseases 0.000 description 2
• 150000008163 sugars Chemical class 0.000 description 2
• 229940124530 sulfonamide Drugs 0.000 description 2
• 150000003456 sulfonamides Chemical class 0.000 description 2
• 150000003457 sulfones Chemical class 0.000 description 2
• 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
• 239000006228 supernatant Substances 0.000 description 2
• 229960000235 temsirolimus Drugs 0.000 description 2
• QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 description 2
• 229940124597 therapeutic agent Drugs 0.000 description 2
• 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 2
• 150000003568 thioethers Chemical class 0.000 description 2
• 150000003573 thiols Chemical class 0.000 description 2
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
• 230000005747 tumor angiogenesis Effects 0.000 description 2
• NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
• AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
• VJLYHTOSFSGXGH-CQSZACIVSA-N (2R)-1-[3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxybenzoyl]pyrrolidine-2-carboxylic acid Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)N2[C@H](CCC2)C(=O)O)C=CC=1 VJLYHTOSFSGXGH-CQSZACIVSA-N 0.000 description 1
• WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
• FNHHVPPSBFQMEL-KQHDFZBMSA-N (3S)-5-N-[(1S,5R)-3-hydroxy-6-bicyclo[3.1.0]hexanyl]-7-N,3-dimethyl-3-phenyl-2H-1-benzofuran-5,7-dicarboxamide Chemical compound CNC(=O)c1cc(cc2c1OC[C@@]2(C)c1ccccc1)C(=O)NC1[C@H]2CC(O)C[C@@H]12 FNHHVPPSBFQMEL-KQHDFZBMSA-N 0.000 description 1
• DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 1
• ZIHSIZMGUBSTSY-UHFFFAOYSA-N 1-(2-methoxyethyl)-5-[2-methyl-6-(1H-1,2,4-triazol-5-yl)pyridin-3-yl]-2H-pyrazine Chemical compound COCCN1CC=NC(=C1)C1=CC=C(N=C1C)C1=NN=CN1 ZIHSIZMGUBSTSY-UHFFFAOYSA-N 0.000 description 1
• KGVOUTZGWDAHLQ-UHFFFAOYSA-N 1-(2-methoxyethyl)-5-[4-methyl-6-(1H-1,2,4-triazol-5-yl)pyridin-3-yl]-2H-pyrazine Chemical compound COCCN1CC=NC(=C1)C=1C=NC(=CC=1C)C1=NNC=N1 KGVOUTZGWDAHLQ-UHFFFAOYSA-N 0.000 description 1
• GECSERWXTPRDHH-UHFFFAOYSA-N 1-ethyl-2,2-dimethyl-5-[2-methyl-4-(1H-1,2,4-triazol-5-yl)phenyl]pyrazine Chemical compound C(C)N1C(C=NC(=C1)C1=C(C=C(C=C1)C1=NN=CN1)C)(C)C GECSERWXTPRDHH-UHFFFAOYSA-N 0.000 description 1
• QSBVRYOBHRNUMN-UHFFFAOYSA-N 1-ethyl-5-[2-methyl-6-(1H-1,2,4-triazol-5-yl)pyridin-3-yl]-2H-pyrazine Chemical compound C(C)N1CC=NC(=C1)C=1C(=NC(=CC=1)C1=NN=CN1)C QSBVRYOBHRNUMN-UHFFFAOYSA-N 0.000 description 1
• 125000006432 1-methyl cyclopropyl group Chemical group [H]C([H])([H])C1(*)C([H])([H])C1([H])[H] 0.000 description 1
• NDJNDVPCBRCEMM-UHFFFAOYSA-N 2,2-dimethyl-5-[2-methyl-4-(1h-1,2,4-triazol-5-yl)phenyl]-1h-pyrazine Chemical compound CC1=CC(C=2NN=CN=2)=CC=C1C1=CNC(C)(C)C=N1 NDJNDVPCBRCEMM-UHFFFAOYSA-N 0.000 description 1
• DMGNAUXWHPUTBF-UHFFFAOYSA-N 2-(1h-indazol-4-yl)-9-(2-methoxyphenyl)-8-oxo-7h-purine-6-carboxamide Chemical compound COC1=CC=CC=C1N1C(=O)NC2=C(C(N)=O)N=C(C=3C=4C=NNC=4C=CC=3)N=C21 DMGNAUXWHPUTBF-UHFFFAOYSA-N 0.000 description 1
• RATVQEQIHJFCQV-UHFFFAOYSA-N 2-(1h-indol-4-yl)-9-(2-methoxyphenyl)-8-oxo-7h-purine-6-carboxamide Chemical compound COC1=CC=CC=C1N1C(=O)NC2=C(C(N)=O)N=C(C=3C=4C=CNC=4C=CC=3)N=C21 RATVQEQIHJFCQV-UHFFFAOYSA-N 0.000 description 1
• UENIQAATCHHLCZ-UHFFFAOYSA-N 2-(1h-indol-5-yl)-8-oxo-9-(2-propan-2-ylphenyl)-7h-purine-6-carboxamide Chemical compound CC(C)C1=CC=CC=C1N1C(=O)NC2=C(C(N)=O)N=C(C=3C=C4C=CNC4=CC=3)N=C21 UENIQAATCHHLCZ-UHFFFAOYSA-N 0.000 description 1
• JAFHXNUYZPIAGR-UHFFFAOYSA-N 2-(2-chloropyridin-3-yl)-8-oxo-9-phenyl-7h-purine-6-carboxamide Chemical compound O=C1NC=2C(C(=O)N)=NC(C=3C(=NC=CC=3)Cl)=NC=2N1C1=CC=CC=C1 JAFHXNUYZPIAGR-UHFFFAOYSA-N 0.000 description 1
• SAPUJGILULUQBA-UHFFFAOYSA-N 2-(2-hydroxyphenyl)-9-(2-methoxyphenyl)purine-6-carboxamide Chemical compound COC1=CC=CC=C1N1C2=NC(C=3C(=CC=CC=3)O)=NC(C(N)=O)=C2N=C1 SAPUJGILULUQBA-UHFFFAOYSA-N 0.000 description 1
• RIABHLXVSQJTOF-UHFFFAOYSA-N 2-(2-methoxypyridin-3-yl)-8-oxo-9-phenyl-7h-purine-6-carboxamide Chemical compound COC1=NC=CC=C1C1=NC(C(N)=O)=C(NC(=O)N2C=3C=CC=CC=3)C2=N1 RIABHLXVSQJTOF-UHFFFAOYSA-N 0.000 description 1
• HHLBMTJZXCKTAO-UHFFFAOYSA-N 2-(3-aminophenyl)-9-(2-methoxyphenyl)-8-oxo-7h-purine-6-carboxamide Chemical compound COC1=CC=CC=C1N1C(=O)NC2=C(C(N)=O)N=C(C=3C=C(N)C=CC=3)N=C21 HHLBMTJZXCKTAO-UHFFFAOYSA-N 0.000 description 1
• GFOPGIMPJRXOJI-UHFFFAOYSA-N 2-(3-cyanophenyl)-9-(2-methoxyphenyl)-8-oxo-7h-purine-6-carboxamide Chemical compound COC1=CC=CC=C1N1C(=O)NC2=C(C(N)=O)N=C(C=3C=C(C=CC=3)C#N)N=C21 GFOPGIMPJRXOJI-UHFFFAOYSA-N 0.000 description 1
• VKBNVPXLCNOFDA-UHFFFAOYSA-N 2-(3-hydroxyanilino)-9-(2-methoxyphenyl)purine-6-carboxamide Chemical compound COC1=CC=CC=C1N1C2=NC(NC=3C=C(O)C=CC=3)=NC(C(N)=O)=C2N=C1 VKBNVPXLCNOFDA-UHFFFAOYSA-N 0.000 description 1
• GVDYOZNGVNCJBW-UHFFFAOYSA-N 2-(3-hydroxyphenyl)-8-(2-methoxyphenyl)-6-oxo-5,7-dihydropteridine-4-carboxamide Chemical compound COC1=CC=CC=C1N1C(N=C(N=C2C(N)=O)C=3C=C(O)C=CC=3)=C2NC(=O)C1 GVDYOZNGVNCJBW-UHFFFAOYSA-N 0.000 description 1
• VHSIMIJLYOSVGV-UHFFFAOYSA-N 2-(3-hydroxyphenyl)-8-oxo-9-(2-phenoxyphenyl)-7h-purine-6-carboxamide Chemical compound O=C1NC=2C(C(=O)N)=NC(C=3C=C(O)C=CC=3)=NC=2N1C1=CC=CC=C1OC1=CC=CC=C1 VHSIMIJLYOSVGV-UHFFFAOYSA-N 0.000 description 1
• SYSDHTKNMONKFW-UHFFFAOYSA-N 2-(3-hydroxyphenyl)-8-oxo-9-(2-phenylphenyl)-7h-purine-6-carboxamide Chemical compound O=C1NC=2C(C(=O)N)=NC(C=3C=C(O)C=CC=3)=NC=2N1C1=CC=CC=C1C1=CC=CC=C1 SYSDHTKNMONKFW-UHFFFAOYSA-N 0.000 description 1
• LPMDNFVSAQNCQG-UHFFFAOYSA-N 2-(3-hydroxyphenyl)-8-oxo-9-(5,6,7,8-tetrahydronaphthalen-1-yl)-7h-purine-6-carboxamide Chemical compound N=1C=2N(C=3C=4CCCCC=4C=CC=3)C(=O)NC=2C(C(=O)N)=NC=1C1=CC=CC(O)=C1 LPMDNFVSAQNCQG-UHFFFAOYSA-N 0.000 description 1
• LQFLMRXTJJJEHH-UHFFFAOYSA-N 2-(3-hydroxyphenyl)-8-oxo-9-[2-(trifluoromethoxy)phenyl]-7h-purine-6-carboxamide Chemical compound O=C1NC=2C(C(=O)N)=NC(C=3C=C(O)C=CC=3)=NC=2N1C1=CC=CC=C1OC(F)(F)F LQFLMRXTJJJEHH-UHFFFAOYSA-N 0.000 description 1
• GTXXPRDATLNTGI-UHFFFAOYSA-N 2-(3-hydroxyphenyl)-8-oxo-9-piperidin-4-yl-7h-purine-6-carboxamide Chemical compound O=C1NC=2C(C(=O)N)=NC(C=3C=C(O)C=CC=3)=NC=2N1C1CCNCC1 GTXXPRDATLNTGI-UHFFFAOYSA-N 0.000 description 1
• REKXWQDSPQOUAG-UHFFFAOYSA-N 2-(3-hydroxyphenyl)-9-(2-methoxyphenyl)purine-6-carboxamide Chemical compound COC1=CC=CC=C1N1C2=NC(C=3C=C(O)C=CC=3)=NC(C(N)=O)=C2N=C1 REKXWQDSPQOUAG-UHFFFAOYSA-N 0.000 description 1
• HQQCFXVFWQOFEI-UHFFFAOYSA-N 2-(3-hydroxyphenyl)-9-(2-methylphenyl)-8-oxo-7h-purine-6-carboxamide Chemical compound CC1=CC=CC=C1N1C(=O)NC2=C(C(N)=O)N=C(C=3C=C(O)C=CC=3)N=C21 HQQCFXVFWQOFEI-UHFFFAOYSA-N 0.000 description 1
• UCIWKRFNWOZMJV-UHFFFAOYSA-N 2-(3-hydroxyphenyl)-9-(2-methylpropyl)-8-oxo-7h-purine-6-carboxamide Chemical compound N=1C(C(N)=O)=C2NC(=O)N(CC(C)C)C2=NC=1C1=CC=CC(O)=C1 UCIWKRFNWOZMJV-UHFFFAOYSA-N 0.000 description 1
• HCNZVXYIFJUNLB-UHFFFAOYSA-N 2-(3-hydroxyphenyl)-9-(4-methoxy-2-methylphenyl)-8-oxo-7h-purine-6-carboxamide Chemical compound CC1=CC(OC)=CC=C1N1C(=O)NC2=C(C(N)=O)N=C(C=3C=C(O)C=CC=3)N=C21 HCNZVXYIFJUNLB-UHFFFAOYSA-N 0.000 description 1
• ODUHNOHLJKOZSD-UHFFFAOYSA-N 2-(3-hydroxyphenyl)-9-(4-methoxyphenyl)-8-oxo-7h-purine-6-carboxamide Chemical compound C1=CC(OC)=CC=C1N1C(=O)NC2=C(C(N)=O)N=C(C=3C=C(O)C=CC=3)N=C21 ODUHNOHLJKOZSD-UHFFFAOYSA-N 0.000 description 1
• YGKQCJUCIVSDMR-UHFFFAOYSA-N 2-(4-cyanophenyl)-9-(2-methoxyphenyl)-8-oxo-7h-purine-6-carboxamide Chemical compound COC1=CC=CC=C1N1C(=O)NC2=C(C(N)=O)N=C(C=3C=CC(=CC=3)C#N)N=C21 YGKQCJUCIVSDMR-UHFFFAOYSA-N 0.000 description 1
• XIHROTCGKRDGKR-UHFFFAOYSA-N 2-(4-hydroxyphenyl)-9-(2-methoxyphenyl)-8-oxo-7H-purine-6-carboxamide Chemical compound COC1=CC=CC=C1N1C(=O)NC2=C(C(N)=O)N=C(C=3C=CC(O)=CC=3)N=C21 XIHROTCGKRDGKR-UHFFFAOYSA-N 0.000 description 1
• RDMDYUQDKJPRED-UHFFFAOYSA-N 2-(5-fluoropyridin-3-yl)-9-(2-methoxyphenyl)-8-oxo-7h-purine-6-carboxamide Chemical compound COC1=CC=CC=C1N1C(=O)NC2=C(C(N)=O)N=C(C=3C=C(F)C=NC=3)N=C21 RDMDYUQDKJPRED-UHFFFAOYSA-N 0.000 description 1
• RSIHMCRNLBDGEN-UHFFFAOYSA-N 2-(8-oxo-2-phenyl-7h-purin-9-yl)acetic acid Chemical compound N=1C=C2NC(=O)N(CC(=O)O)C2=NC=1C1=CC=CC=C1 RSIHMCRNLBDGEN-UHFFFAOYSA-N 0.000 description 1
• IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical class O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 1
• KQTHSEWLOBJIOZ-UHFFFAOYSA-N 2-[2-(hydroxymethyl)anilino]-9-(2-methoxyphenyl)-8-oxo-7h-purine-6-carboxamide Chemical compound COC1=CC=CC=C1N1C(=O)NC2=C(C(N)=O)N=C(NC=3C(=CC=CC=3)CO)N=C21 KQTHSEWLOBJIOZ-UHFFFAOYSA-N 0.000 description 1
• BGTLIODMWIWDTM-UHFFFAOYSA-N 2-[3-(aminomethyl)phenyl]-9-(2-methoxyphenyl)-8-oxo-7h-purine-6-carboxamide Chemical compound COC1=CC=CC=C1N1C(=O)NC2=C(C(N)=O)N=C(C=3C=C(CN)C=CC=3)N=C21 BGTLIODMWIWDTM-UHFFFAOYSA-N 0.000 description 1
• RLVWQYYMNVREPW-UHFFFAOYSA-N 2-[3-(hydroxymethyl)anilino]-9-(2-methoxyphenyl)-8-oxo-7h-purine-6-carboxamide Chemical compound COC1=CC=CC=C1N1C(=O)NC2=C(C(N)=O)N=C(NC=3C=C(CO)C=CC=3)N=C21 RLVWQYYMNVREPW-UHFFFAOYSA-N 0.000 description 1
• BVNVZYCZFQGDFQ-UHFFFAOYSA-N 2-[4-(aminomethyl)phenyl]-9-(2-methoxyphenyl)-8-oxo-7h-purine-6-carboxamide Chemical compound COC1=CC=CC=C1N1C(=O)NC2=C(C(N)=O)N=C(C=3C=CC(CN)=CC=3)N=C21 BVNVZYCZFQGDFQ-UHFFFAOYSA-N 0.000 description 1
• MVZBIMBJTYQZBA-UHFFFAOYSA-N 2-[5-[1-(2,2-dimethylpropyl)-2H-pyrazin-5-yl]pyridin-2-yl]propan-2-ol Chemical compound CC(C)(C)CN1CC=NC(=C1)C1=CC=C(N=C1)C(C)(C)O MVZBIMBJTYQZBA-UHFFFAOYSA-N 0.000 description 1
• TVCLRBNAHKNVDM-UHFFFAOYSA-N 2-[5-[1-(2-methylpropyl)-2H-pyrazin-5-yl]pyridin-2-yl]propan-2-ol Chemical compound CC(C)CN1CC=NC(=C1)C1=CC=C(N=C1)C(C)(C)O TVCLRBNAHKNVDM-UHFFFAOYSA-N 0.000 description 1
• YTBJMPWPJNTECW-UHFFFAOYSA-N 2-[5-[1-(3-methoxypropyl)-2h-pyrazin-5-yl]pyridin-2-yl]propan-2-ol Chemical compound COCCCN1CC=NC(C=2C=NC(=CC=2)C(C)(C)O)=C1 YTBJMPWPJNTECW-UHFFFAOYSA-N 0.000 description 1
• GYKRHWFQEUPOCW-UHFFFAOYSA-N 2-[5-[1-(cyclohexylmethyl)-2H-pyrazin-5-yl]pyridin-2-yl]propan-2-ol Chemical compound CC(C)(O)C1=CC=C(C=N1)C1=CN(CC2CCCCC2)CC=N1 GYKRHWFQEUPOCW-UHFFFAOYSA-N 0.000 description 1
• VVTOXAWPJURYJC-UHFFFAOYSA-N 2-[5-[1-(cyclopentylmethyl)-2H-pyrazin-5-yl]pyridin-2-yl]propan-2-ol Chemical compound CC(C)(O)C1=CC=C(C=N1)C1=CN(CC2CCCC2)CC=N1 VVTOXAWPJURYJC-UHFFFAOYSA-N 0.000 description 1
• WSXACIXIKNSFCD-UHFFFAOYSA-N 2-[5-[1-(cyclopropylmethyl)-2H-pyrazin-5-yl]pyridin-2-yl]propan-2-ol Chemical compound C1(CC1)CN1CC=NC(=C1)C=1C=NC(=CC=1)C(C)(C)O WSXACIXIKNSFCD-UHFFFAOYSA-N 0.000 description 1
• UXGVMFHEKMGWMA-UHFFFAOYSA-N 2-benzofuran Chemical compound C1=CC=CC2=COC=C21 UXGVMFHEKMGWMA-UHFFFAOYSA-N 0.000 description 1
• SMNDYUVBFMFKNZ-UHFFFAOYSA-N 2-furoic acid Chemical compound OC(=O)C1=CC=CO1 SMNDYUVBFMFKNZ-UHFFFAOYSA-N 0.000 description 1
• CZUXUTZOEIRAGY-UHFFFAOYSA-N 2-methyl-8-oxo-9-phenyl-7h-purine-6-carboxamide Chemical compound C12=NC(C)=NC(C(N)=O)=C2NC(=O)N1C1=CC=CC=C1 CZUXUTZOEIRAGY-UHFFFAOYSA-N 0.000 description 1
• 125000005916 2-methylpentyl group Chemical group 0.000 description 1
• 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
• UZZACWMLVMJSQP-UHFFFAOYSA-N 3-[6-carbamoyl-9-(2-methoxyphenyl)-8-oxo-7h-purin-2-yl]benzoic acid Chemical compound COC1=CC=CC=C1N1C(=O)NC2=C(C(N)=O)N=C(C=3C=C(C=CC=3)C(O)=O)N=C21 UZZACWMLVMJSQP-UHFFFAOYSA-N 0.000 description 1
• 125000005917 3-methylpentyl group Chemical group 0.000 description 1
• XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
• QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
• 125000001572 5'-adenylyl group Chemical group C=12N=C([H])N=C(N([H])[H])C=1N=C([H])N2[C@@]1([H])[C@@](O[H])([H])[C@@](O[H])([H])[C@](C(OP(=O)(O[H])[*])([H])[H])([H])O1 0.000 description 1
• 125000001417 5'-guanylyl group Chemical group C=12N=C(N([H])[H])N([H])C(=O)C=1N=C([H])N2[C@@]1([H])[C@@](O[H])([H])[C@@](O[H])([H])[C@](C(OP(=O)(O[H])[*])([H])[H])([H])O1 0.000 description 1
• ANNMYWNLLWTYAU-UHFFFAOYSA-N 5-[1-[2-(oxan-4-yl)ethyl]-2H-pyrazin-5-yl]-1H-indazole Chemical compound N1N=CC2=CC(=CC=C12)C1=CN(CC=N1)CCC1CCOCC1 ANNMYWNLLWTYAU-UHFFFAOYSA-N 0.000 description 1
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
• GKXCVPWPQLVDEH-UHFFFAOYSA-N 8-oxo-9-(2-propan-2-ylphenyl)-2-[4-(1h-1,2,4-triazol-5-yl)phenyl]-7h-purine-6-carboxamide Chemical compound CC(C)C1=CC=CC=C1N1C(=O)NC2=C(C(N)=O)N=C(C=3C=CC(=CC=3)C3=NNC=N3)N=C21 GKXCVPWPQLVDEH-UHFFFAOYSA-N 0.000 description 1
• PBUPUHCPBXBSKQ-UHFFFAOYSA-N 8-oxo-9-(2-propan-2-ylphenyl)-2-[4-(2h-triazol-4-yl)phenyl]-7h-purine-6-carboxamide Chemical compound CC(C)C1=CC=CC=C1N1C(=O)NC2=C(C(N)=O)N=C(C=3C=CC(=CC=3)C=3NN=NC=3)N=C21 PBUPUHCPBXBSKQ-UHFFFAOYSA-N 0.000 description 1
• FQRXLNIVEFVHSE-UHFFFAOYSA-N 9-(2,3-dihydro-1h-inden-1-yl)-2-(3-hydroxyphenyl)-8-oxo-7h-purine-6-carboxamide Chemical compound N=1C=2N(C3C4=CC=CC=C4CC3)C(=O)NC=2C(C(=O)N)=NC=1C1=CC=CC(O)=C1 FQRXLNIVEFVHSE-UHFFFAOYSA-N 0.000 description 1
• NINLEEBDKKNBKP-UHFFFAOYSA-N 9-(2,4-dichlorophenyl)-2-(3-hydroxyphenyl)-8-oxo-7h-purine-6-carboxamide Chemical compound O=C1NC=2C(C(=O)N)=NC(C=3C=C(O)C=CC=3)=NC=2N1C1=CC=C(Cl)C=C1Cl NINLEEBDKKNBKP-UHFFFAOYSA-N 0.000 description 1
• RIWTVOMGWCAJRC-UHFFFAOYSA-N 9-(2,6-difluorophenyl)-2-(3-hydroxyphenyl)-8-oxo-7h-purine-6-carboxamide Chemical compound O=C1NC=2C(C(=O)N)=NC(C=3C=C(O)C=CC=3)=NC=2N1C1=C(F)C=CC=C1F RIWTVOMGWCAJRC-UHFFFAOYSA-N 0.000 description 1
• MPZHAQZONBYNJF-UHFFFAOYSA-N 9-(2-cyclopentylphenyl)-2-(3-hydroxyphenyl)-8-oxo-7h-purine-6-carboxamide Chemical compound O=C1NC=2C(C(=O)N)=NC(C=3C=C(O)C=CC=3)=NC=2N1C1=CC=CC=C1C1CCCC1 MPZHAQZONBYNJF-UHFFFAOYSA-N 0.000 description 1
• ZIZGILIJVGTDJQ-UHFFFAOYSA-N 9-(2-ethylphenyl)-2-(3-hydroxyphenyl)-8-oxo-7h-purine-6-carboxamide Chemical compound CCC1=CC=CC=C1N1C(=O)NC2=C(C(N)=O)N=C(C=3C=C(O)C=CC=3)N=C21 ZIZGILIJVGTDJQ-UHFFFAOYSA-N 0.000 description 1
• SEBCRFUXBLJQHQ-UHFFFAOYSA-N 9-(2-hydroxyethyl)-2-methylpurine-6-carboxamide Chemical compound CC1=NC(C(N)=O)=C2N=CN(CCO)C2=N1 SEBCRFUXBLJQHQ-UHFFFAOYSA-N 0.000 description 1
• FBECNQNZSXSUKI-UHFFFAOYSA-N 9-(2-hydroxyethyl)-2-prop-1-enylpurine-6-carboxamide Chemical compound CC=CC1=NC(C(N)=O)=C2N=CN(CCO)C2=N1 FBECNQNZSXSUKI-UHFFFAOYSA-N 0.000 description 1
• QMZSCBSIWQMGJK-UHFFFAOYSA-N 9-(2-methoxyphenyl)-2-(6-methoxypyridin-3-yl)-8-oxo-7h-purine-6-carboxamide Chemical compound C1=NC(OC)=CC=C1C1=NC(C(N)=O)=C(NC(=O)N2C=3C(=CC=CC=3)OC)C2=N1 QMZSCBSIWQMGJK-UHFFFAOYSA-N 0.000 description 1
• RKNLFSHHRWRJMY-UHFFFAOYSA-N 9-(2-methoxyphenyl)-8-oxo-2-[3-(trifluoromethoxy)phenyl]-7h-purine-6-carboxamide Chemical compound COC1=CC=CC=C1N1C(=O)NC2=C(C(N)=O)N=C(C=3C=C(OC(F)(F)F)C=CC=3)N=C21 RKNLFSHHRWRJMY-UHFFFAOYSA-N 0.000 description 1
• AGLIYPCDJKUNQG-UHFFFAOYSA-N 9-(2-methoxyphenyl)-8-oxo-2-pyridin-4-yl-7h-purine-6-carboxamide Chemical compound COC1=CC=CC=C1N1C(=O)NC2=C(C(N)=O)N=C(C=3C=CN=CC=3)N=C21 AGLIYPCDJKUNQG-UHFFFAOYSA-N 0.000 description 1
• BCPJYICCAMLZSA-UHFFFAOYSA-N 9-(2-methoxyphenyl)-8-oxo-2-quinolin-5-yl-7h-purine-6-carboxamide Chemical compound COC1=CC=CC=C1N1C(=O)NC2=C(C(N)=O)N=C(C=3C4=CC=CN=C4C=CC=3)N=C21 BCPJYICCAMLZSA-UHFFFAOYSA-N 0.000 description 1
• JBRLBYKWHKNIRV-UHFFFAOYSA-N 9-(2-tert-butylphenyl)-2-(3-hydroxyphenyl)-8-oxo-7h-purine-6-carboxamide Chemical compound CC(C)(C)C1=CC=CC=C1N1C(=O)NC2=C(C(N)=O)N=C(C=3C=C(O)C=CC=3)N=C21 JBRLBYKWHKNIRV-UHFFFAOYSA-N 0.000 description 1
• XVQMHZWTNIABIT-UHFFFAOYSA-N 9-(3-methylphenyl)-8-oxo-2-pyridin-3-yl-7h-purine-6-carboxamide Chemical compound CC1=CC=CC(N2C(NC3=C(C(N)=O)N=C(N=C32)C=2C=NC=CC=2)=O)=C1 XVQMHZWTNIABIT-UHFFFAOYSA-N 0.000 description 1
• OTYVVIIBUQVJFU-UHFFFAOYSA-N 9-benzyl-2-(3-hydroxyphenyl)-8-oxo-7h-purine-6-carboxamide Chemical compound O=C1NC=2C(C(=O)N)=NC(C=3C=C(O)C=CC=3)=NC=2N1CC1=CC=CC=C1 OTYVVIIBUQVJFU-UHFFFAOYSA-N 0.000 description 1
• JRCFAROYAPNJQJ-UHFFFAOYSA-N 9-benzyl-8-oxo-2-pyridin-3-yl-7h-purine-6-carboxamide Chemical compound O=C1NC=2C(C(=O)N)=NC(C=3C=NC=CC=3)=NC=2N1CC1=CC=CC=C1 JRCFAROYAPNJQJ-UHFFFAOYSA-N 0.000 description 1
• OCXWDXMLAQPCKK-UHFFFAOYSA-N 9-benzylpurine-2,6-dicarboxamide Chemical compound C12=NC(C(=O)N)=NC(C(N)=O)=C2N=CN1CC1=CC=CC=C1 OCXWDXMLAQPCKK-UHFFFAOYSA-N 0.000 description 1
• KSDCBHGJKJWKKW-UHFFFAOYSA-N 9-cycloheptyl-8-oxo-2-pyridin-3-yl-7h-purine-6-carboxamide Chemical compound O=C1NC=2C(C(=O)N)=NC(C=3C=NC=CC=3)=NC=2N1C1CCCCCC1 KSDCBHGJKJWKKW-UHFFFAOYSA-N 0.000 description 1
• IDOABCJJJSSICD-UHFFFAOYSA-N 9-cyclohexyl-2-(3-hydroxyphenyl)-8-oxo-7h-purine-6-carboxamide Chemical compound O=C1NC=2C(C(=O)N)=NC(C=3C=C(O)C=CC=3)=NC=2N1C1CCCCC1 IDOABCJJJSSICD-UHFFFAOYSA-N 0.000 description 1
• DKWQALXHTVXPHP-UHFFFAOYSA-N 9-methyl-8-oxo-2-pyridin-3-yl-7h-purine-6-carboxamide Chemical compound N=1C(C(N)=O)=C2NC(=O)N(C)C2=NC=1C1=CC=CN=C1 DKWQALXHTVXPHP-UHFFFAOYSA-N 0.000 description 1
• AENLBSGSASHWDU-UHFFFAOYSA-N 9-phenyl-2-pyridin-3-ylpurine-6-carboxamide Chemical compound C1=NC=2C(C(=O)N)=NC(C=3C=NC=CC=3)=NC=2N1C1=CC=CC=C1 AENLBSGSASHWDU-UHFFFAOYSA-N 0.000 description 1
• 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
• 229920001817 Agar Polymers 0.000 description 1
• 239000005995 Aluminium silicate Substances 0.000 description 1
• 244000144725 Amygdalus communis Species 0.000 description 1
• 235000011437 Amygdalus communis Nutrition 0.000 description 1
• 201000001320 Atherosclerosis Diseases 0.000 description 1
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
• 239000005711 Benzoic acid Substances 0.000 description 1
• ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical group N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
• ZLNBWRIUBYDYQS-BJHJDKERSA-N C1C[C@@H](COC)CC[C@H]1N1C(=O)NC2=C(C(N)=O)N=C(C=3C=C(O)C=CC=3)N=C21 Chemical compound C1C[C@@H](COC)CC[C@H]1N1C(=O)NC2=C(C(N)=O)N=C(C=3C=C(O)C=CC=3)N=C21 ZLNBWRIUBYDYQS-BJHJDKERSA-N 0.000 description 1
• XMLNCNLPPWLQFT-XYPYZODXSA-N C1C[C@@H](N)CC[C@@H]1N1C(=O)NC2=C(C(N)=O)N=C(C=3C=C(O)C=CC=3)N=C21 Chemical compound C1C[C@@H](N)CC[C@@H]1N1C(=O)NC2=C(C(N)=O)N=C(C=3C=C(O)C=CC=3)N=C21 XMLNCNLPPWLQFT-XYPYZODXSA-N 0.000 description 1
• FKEBCODXEMZWJX-AULYBMBSSA-N C1C[C@@H](OC)CC[C@@H]1N1C(=O)NC2=C(C(N)=O)N=C(C=3C=C(O)C=CC=3)N=C21 Chemical compound C1C[C@@H](OC)CC[C@@H]1N1C(=O)NC2=C(C(N)=O)N=C(C=3C=C(O)C=CC=3)N=C21 FKEBCODXEMZWJX-AULYBMBSSA-N 0.000 description 1
• FKEBCODXEMZWJX-BJHJDKERSA-N C1C[C@@H](OC)CC[C@H]1N1C(=O)NC2=C(C(N)=O)N=C(C=3C=C(O)C=CC=3)N=C21 Chemical compound C1C[C@@H](OC)CC[C@H]1N1C(=O)NC2=C(C(N)=O)N=C(C=3C=C(O)C=CC=3)N=C21 FKEBCODXEMZWJX-BJHJDKERSA-N 0.000 description 1
• JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
• XMJYDDXJBNFUMN-PHIMTYICSA-N COC1=CC=CC=C1N1C(=O)NC2=C(C(N)=O)N=C(N[C@H]3CC[C@@H](O)CC3)N=C21 Chemical compound COC1=CC=CC=C1N1C(=O)NC2=C(C(N)=O)N=C(N[C@H]3CC[C@@H](O)CC3)N=C21 XMJYDDXJBNFUMN-PHIMTYICSA-N 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
• 239000004215 Carbon black (E152) Substances 0.000 description 1
• OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
• 241000700199 Cavia porcellus Species 0.000 description 1
• 241000282693 Cercopithecidae Species 0.000 description 1
• 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
• 241000207199 Citrus Species 0.000 description 1
• 229940126657 Compound 17 Drugs 0.000 description 1
• 229920002261 Corn starch Polymers 0.000 description 1
• 108090000695 Cytokines Proteins 0.000 description 1
• 102000004127 Cytokines Human genes 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
• 108020004414 DNA Proteins 0.000 description 1
• 230000005778 DNA damage Effects 0.000 description 1
• 231100000277 DNA damage Toxicity 0.000 description 1
• 238000001061 Dunnett's test Methods 0.000 description 1
• 241000283073 Equus caballus Species 0.000 description 1
• 239000001856 Ethyl cellulose Substances 0.000 description 1
• ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
• PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 241000287828 Gallus gallus Species 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• 229920002907 Guar gum Polymers 0.000 description 1
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 206010061218 Inflammation Diseases 0.000 description 1
• 241000764773 Inna Species 0.000 description 1
• 206010023439 Kidney transplant rejection Diseases 0.000 description 1
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
• 239000004472 Lysine Substances 0.000 description 1
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
• 241000124008 Mammalia Species 0.000 description 1
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
• 241000699666 Mus <mouse, genus> Species 0.000 description 1
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
• HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
• MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
• 101100194003 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) rco-3 gene Proteins 0.000 description 1
• 239000000020 Nitrocellulose Substances 0.000 description 1
• 208000008589 Obesity Diseases 0.000 description 1
• 102000043276 Oncogene Human genes 0.000 description 1
• 108700020796 Oncogene Proteins 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 208000002193 Pain Diseases 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 241000009328 Perro Species 0.000 description 1
• 241000286209 Phasianidae Species 0.000 description 1
• 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
• 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
• 102000052575 Proto-Oncogene Human genes 0.000 description 1
• 108700020978 Proto-Oncogene Proteins 0.000 description 1
• 241000700159 Rattus Species 0.000 description 1
• 206010038111 Recurrent cancer Diseases 0.000 description 1
• 241000283984 Rodentia Species 0.000 description 1
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
• 229910020874 Sn-M Inorganic materials 0.000 description 1
• 229910008890 Sn—M Inorganic materials 0.000 description 1
• UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
• DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
• 235000021355 Stearic acid Nutrition 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
• NINIDFKCEFEMDL-AKLPVKDBSA-N Sulfur-35 Chemical compound [35S] NINIDFKCEFEMDL-AKLPVKDBSA-N 0.000 description 1
• 241000282898 Sus scrofa Species 0.000 description 1
• 244000299461 Theobroma cacao Species 0.000 description 1
• 235000009470 Theobroma cacao Nutrition 0.000 description 1
• YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
• 208000026911 Tuberous sclerosis complex Diseases 0.000 description 1
• 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
• 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
• 229940127538 Vascular Endothelial Growth Factor Receptor Inhibitors Drugs 0.000 description 1
• 208000036142 Viral infection Diseases 0.000 description 1
• 240000008042 Zea mays Species 0.000 description 1
• 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
• 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
• PNDPGZBMCMUPRI-XXSWNUTMSA-N [125I][125I] Chemical compound [125I][125I] PNDPGZBMCMUPRI-XXSWNUTMSA-N 0.000 description 1
• 230000002159 abnormal effect Effects 0.000 description 1
• 238000009825 accumulation Methods 0.000 description 1
• 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
• 239000004480 active ingredient Substances 0.000 description 1
• 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 125000005426 adeninyl group Chemical group N1=C(N=C2N=CNC2=C1N)* 0.000 description 1
• 239000008272 agar Substances 0.000 description 1
• 235000010419 agar Nutrition 0.000 description 1
• 229960001126 alginic acid Drugs 0.000 description 1
• 150000004781 alginic acids Chemical class 0.000 description 1
• 125000002877 alkyl aryl group Chemical group 0.000 description 1
• 125000005119 alkyl cycloalkyl group Chemical group 0.000 description 1
• 125000005907 alkyl ester group Chemical group 0.000 description 1
• 125000004656 alkyl sulfonylamino group Chemical group 0.000 description 1
• 235000020224 almond Nutrition 0.000 description 1
• 229910052782 aluminium Inorganic materials 0.000 description 1
• XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
• 235000012211 aluminium silicate Nutrition 0.000 description 1
• CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
• 229940063655 aluminum stearate Drugs 0.000 description 1
• 150000001408 amides Chemical class 0.000 description 1
• 238000000540 analysis of variance Methods 0.000 description 1
• 230000003322 aneuploid effect Effects 0.000 description 1
• 208000036878 aneuploidy Diseases 0.000 description 1
• 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
• 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 230000003078 antioxidant effect Effects 0.000 description 1
• 235000015197 apple juice Nutrition 0.000 description 1
• 229910052785 arsenic Inorganic materials 0.000 description 1
• 125000002102 aryl alkyloxo group Chemical group 0.000 description 1
• 238000003149 assay kit Methods 0.000 description 1
• 230000002238 attenuated effect Effects 0.000 description 1
• 125000005602 azabenzimidazolyl group Chemical group 0.000 description 1
• 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 description 1
• 125000002393 azetidinyl group Chemical group 0.000 description 1
• 125000004069 aziridinyl group Chemical group 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• 239000000440 bentonite Substances 0.000 description 1
• 229910000278 bentonite Inorganic materials 0.000 description 1
• 235000012216 bentonite Nutrition 0.000 description 1
• SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
• 125000005605 benzo group Chemical group 0.000 description 1
• 235000010233 benzoic acid Nutrition 0.000 description 1
• 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
• 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
• 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
• 125000002619 bicyclic group Chemical group 0.000 description 1
• 230000015572 biosynthetic process Effects 0.000 description 1
• 239000007975 buffered saline Substances 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 229910000019 calcium carbonate Inorganic materials 0.000 description 1
• 235000010216 calcium carbonate Nutrition 0.000 description 1
• FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
• 239000001354 calcium citrate Substances 0.000 description 1
• CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
• 235000013539 calcium stearate Nutrition 0.000 description 1
• 239000008116 calcium stearate Substances 0.000 description 1
• OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Inorganic materials [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
• 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 1
• 125000002837 carbocyclic group Chemical group 0.000 description 1
• 150000001721 carbon Chemical group 0.000 description 1
• 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 239000003729 cation exchange resin Substances 0.000 description 1
• 229940023913 cation exchange resins Drugs 0.000 description 1
• 230000021164 cell adhesion Effects 0.000 description 1
• 230000006369 cell cycle progression Effects 0.000 description 1
• 230000024245 cell differentiation Effects 0.000 description 1
• 230000003915 cell function Effects 0.000 description 1
• 230000010261 cell growth Effects 0.000 description 1
• 235000013339 cereals Nutrition 0.000 description 1
• 239000003638 chemical reducing agent Substances 0.000 description 1
• VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
• 229960002023 chloroprocaine Drugs 0.000 description 1
• OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
• 229960001231 choline Drugs 0.000 description 1
• 208000037976 chronic inflammation Diseases 0.000 description 1
• 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
• 235000020971 citrus fruits Nutrition 0.000 description 1
• 238000003776 cleavage reaction Methods 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 238000000576 coating method Methods 0.000 description 1
• 235000019868 cocoa butter Nutrition 0.000 description 1
• 229940110456 cocoa butter Drugs 0.000 description 1
• 238000004891 communication Methods 0.000 description 1
• 229940126208 compound 22 Drugs 0.000 description 1
• ONCCWDRMOZMNSM-FBCQKBJTSA-N compound Z Chemical compound N1=C2C(=O)NC(N)=NC2=NC=C1C(=O)[C@H]1OP(O)(=O)OC[C@H]1O ONCCWDRMOZMNSM-FBCQKBJTSA-N 0.000 description 1
• 239000012141 concentrate Substances 0.000 description 1
• 235000008504 concentrate Nutrition 0.000 description 1
• 238000012790 confirmation Methods 0.000 description 1
• 230000037011 constitutive activity Effects 0.000 description 1
• 238000010276 construction Methods 0.000 description 1
• 230000001276 controlling effect Effects 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 235000005822 corn Nutrition 0.000 description 1
• 125000006165 cyclic alkyl group Chemical group 0.000 description 1
• 125000004367 cycloalkylaryl group Chemical group 0.000 description 1
• 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
• 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
• 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
• 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 1
• 238000013461 design Methods 0.000 description 1
• 239000000032 diagnostic agent Substances 0.000 description 1
• 229940039227 diagnostic agent Drugs 0.000 description 1
• ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
• 229940043237 diethanolamine Drugs 0.000 description 1
• 239000013024 dilution buffer Substances 0.000 description 1
• 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
• 239000007884 disintegrant Substances 0.000 description 1
• 239000002270 dispersing agent Substances 0.000 description 1
• VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
• 239000003596 drug target Substances 0.000 description 1
• 238000007908 dry granulation Methods 0.000 description 1
• 230000008482 dysregulation Effects 0.000 description 1
• 210000005069 ears Anatomy 0.000 description 1
• 230000005014 ectopic expression Effects 0.000 description 1
• 238000011984 electrochemiluminescence immunoassay Methods 0.000 description 1
• 230000032050 esterification Effects 0.000 description 1
• 238000005886 esterification reaction Methods 0.000 description 1
• 235000019325 ethyl cellulose Nutrition 0.000 description 1
• 229920001249 ethyl cellulose Polymers 0.000 description 1
• 229940012017 ethylenediamine Drugs 0.000 description 1
• 238000011049 filling Methods 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• 235000019634 flavors Nutrition 0.000 description 1
• 235000013312 flour Nutrition 0.000 description 1
• 238000000684 flow cytometry Methods 0.000 description 1
• 238000001917 fluorescence detection Methods 0.000 description 1
• 235000010855 food raising agent Nutrition 0.000 description 1
• 238000009472 formulation Methods 0.000 description 1
• 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
• 230000006870 function Effects 0.000 description 1
• 210000001035 gastrointestinal tract Anatomy 0.000 description 1
• 210000004907 gland Anatomy 0.000 description 1
• 235000001727 glucose Nutrition 0.000 description 1
• RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
• 239000003102 growth factor Substances 0.000 description 1
• 235000010417 guar gum Nutrition 0.000 description 1
• 239000000665 guar gum Substances 0.000 description 1
• 229960002154 guar gum Drugs 0.000 description 1
• 150000003278 haem Chemical class 0.000 description 1
• 125000005844 heterocyclyloxy group Chemical group 0.000 description 1
• 229930195733 hydrocarbon Natural products 0.000 description 1
• 150000002430 hydrocarbons Chemical class 0.000 description 1
• 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
• IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
• 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
• 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
• 239000001341 hydroxy propyl starch Substances 0.000 description 1
• 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
• 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
• 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
• 235000013828 hydroxypropyl starch Nutrition 0.000 description 1
• 239000012216 imaging agent Substances 0.000 description 1
• 125000005945 imidazopyridyl group Chemical group 0.000 description 1
• 150000002466 imines Chemical class 0.000 description 1
• 239000003547 immunosorbent Substances 0.000 description 1
• 230000006882 induction of apoptosis Effects 0.000 description 1
• 208000027866 inflammatory disease Diseases 0.000 description 1
• 230000004054 inflammatory process Effects 0.000 description 1
• 238000003331 infrared imaging Methods 0.000 description 1
• 150000007529 inorganic bases Chemical class 0.000 description 1
• 239000011630 iodine Substances 0.000 description 1
• 229940044173 iodine-125 Drugs 0.000 description 1
• 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
• 125000001786 isothiazolyl group Chemical group 0.000 description 1
• NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 150000002632 lipids Chemical class 0.000 description 1
• 229910052744 lithium Inorganic materials 0.000 description 1
• 239000012160 loading buffer Substances 0.000 description 1
• 238000011068 loading method Methods 0.000 description 1
• 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
• 208000002780 macular degeneration Diseases 0.000 description 1
• 239000011777 magnesium Substances 0.000 description 1
• 238000004519 manufacturing process Methods 0.000 description 1
• 239000011159 matrix material Substances 0.000 description 1
• 229960003194 meglumine Drugs 0.000 description 1
• 238000002844 melting Methods 0.000 description 1
• 230000008018 melting Effects 0.000 description 1
• 229940041616 menthol Drugs 0.000 description 1
• 239000002207 metabolite Substances 0.000 description 1
• 206010061289 metastatic neoplasm Diseases 0.000 description 1
• 208000010658 metastatic prostate carcinoma Diseases 0.000 description 1
• HNQIVZYLYMDVSB-NJFSPNSNSA-N methanesulfonamide Chemical compound [14CH3]S(N)(=O)=O HNQIVZYLYMDVSB-NJFSPNSNSA-N 0.000 description 1
• 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
• 229960002216 methylparaben Drugs 0.000 description 1
• 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
• 239000003094 microcapsule Substances 0.000 description 1
• 229940016286 microcrystalline cellulose Drugs 0.000 description 1
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
• 239000008108 microcrystalline cellulose Substances 0.000 description 1
• 239000004005 microsphere Substances 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 230000004048 modification Effects 0.000 description 1
• 238000012986 modification Methods 0.000 description 1
• 238000007837 multiplex assay Methods 0.000 description 1
• 208000033937 musculocontractural type Ehlers-Danlos syndrome Diseases 0.000 description 1
• 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
• 230000017066 negative regulation of growth Effects 0.000 description 1
• 230000001613 neoplastic effect Effects 0.000 description 1
• 201000011519 neuroendocrine tumor Diseases 0.000 description 1
• 229920001220 nitrocellulos Polymers 0.000 description 1
• 238000010899 nucleation Methods 0.000 description 1
• 239000002777 nucleoside Substances 0.000 description 1
• 125000003835 nucleoside group Chemical group 0.000 description 1
• 235000020824 obesity Nutrition 0.000 description 1
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
• 239000003921 oil Substances 0.000 description 1
• 235000019198 oils Nutrition 0.000 description 1
• 231100000590 oncogenic Toxicity 0.000 description 1
• 230000002246 oncogenic effect Effects 0.000 description 1
• 238000011275 oncology therapy Methods 0.000 description 1
• 238000001543 one-way ANOVA Methods 0.000 description 1
• 235000015205 orange juice Nutrition 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 150000007530 organic bases Chemical class 0.000 description 1
• 125000001715 oxadiazolyl group Chemical group 0.000 description 1
• 150000002921 oxetanes Chemical class 0.000 description 1
• 125000005489 p-toluenesulfonic acid group Chemical class 0.000 description 1
• 239000003182 parenteral nutrition solution Substances 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 230000007170 pathology Effects 0.000 description 1
• 235000019271 petrolatum Nutrition 0.000 description 1
• 239000008177 pharmaceutical agent Substances 0.000 description 1
• WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
• 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
• 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
• IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical compound NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 description 1
• 238000011518 platinum-based chemotherapy Methods 0.000 description 1
• SJWPTBFNZAZFSH-UHFFFAOYSA-N pmpp Chemical compound C1CCSC2=NC=NC3=C2N=CN3CCCN2C(=O)N(C)C(=O)C1=C2 SJWPTBFNZAZFSH-UHFFFAOYSA-N 0.000 description 1
• 229920006324 polyoxymethylene Polymers 0.000 description 1
• 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• 229910052700 potassium Inorganic materials 0.000 description 1
• 229920001592 potato starch Polymers 0.000 description 1
• 229920003124 powdered cellulose Polymers 0.000 description 1
• 235000019814 powdered cellulose Nutrition 0.000 description 1
• 238000004321 preservation Methods 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 230000002335 preservative effect Effects 0.000 description 1
• 238000003825 pressing Methods 0.000 description 1
• MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
• 229960004919 procaine Drugs 0.000 description 1
• 238000004393 prognosis Methods 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 238000011321 prophylaxis Methods 0.000 description 1
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
• 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
• 229960003415 propylparaben Drugs 0.000 description 1
• 239000003223 protective agent Substances 0.000 description 1
• 238000000159 protein binding assay Methods 0.000 description 1
• 239000003909 protein kinase inhibitor Substances 0.000 description 1
• LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 1
• DDSCCYSKFCZQMP-UHFFFAOYSA-N purine-6-caboxamide Chemical compound NC(=O)C1=NC=NC2=C1N=CN2 DDSCCYSKFCZQMP-UHFFFAOYSA-N 0.000 description 1
• 150000003217 pyrazoles Chemical class 0.000 description 1
• 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
• 125000002755 pyrazolinyl group Chemical group 0.000 description 1
• ILVXOBCQQYKLDS-UHFFFAOYSA-N pyridine N-oxide Chemical compound [O-][N+]1=CC=CC=C1 ILVXOBCQQYKLDS-UHFFFAOYSA-N 0.000 description 1
• 125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• 125000001422 pyrrolinyl group Chemical group 0.000 description 1
• 125000006085 pyrrolopyridyl group Chemical group 0.000 description 1
• 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
• 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
• 230000008707 rearrangement Effects 0.000 description 1
• 230000000306 recurrent effect Effects 0.000 description 1
• 108010054624 red fluorescent protein Proteins 0.000 description 1
• 230000022983 regulation of cell cycle Effects 0.000 description 1
• 230000001105 regulatory effect Effects 0.000 description 1
• 230000000717 retained effect Effects 0.000 description 1
• 239000012146 running buffer Substances 0.000 description 1
• 230000007017 scission Effects 0.000 description 1
• 239000003566 sealing material Substances 0.000 description 1
• 230000009291 secondary effect Effects 0.000 description 1
• 230000035945 sensitivity Effects 0.000 description 1
• 238000013207 serial dilution Methods 0.000 description 1
• 230000019491 signal transduction Effects 0.000 description 1
• 230000011664 signaling Effects 0.000 description 1
• RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
• 235000012239 silicon dioxide Nutrition 0.000 description 1
• 239000011734 sodium Substances 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
• 235000010234 sodium benzoate Nutrition 0.000 description 1
• 239000004299 sodium benzoate Substances 0.000 description 1
• 229960003885 sodium benzoate Drugs 0.000 description 1
• 229940001607 sodium bisulfite Drugs 0.000 description 1
• 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
• 239000011780 sodium chloride Substances 0.000 description 1
• 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
• CMZUMMUJMWNLFH-UHFFFAOYSA-N sodium metavanadate Chemical compound [Na+].[O-][V](=O)=O CMZUMMUJMWNLFH-UHFFFAOYSA-N 0.000 description 1
• 235000010268 sodium methyl p-hydroxybenzoate Nutrition 0.000 description 1
• HJHVQCXHVMGZNC-JCJNLNMISA-M sodium;(2z)-2-[(3r,4s,5s,8s,9s,10s,11r,13r,14s,16s)-16-acetyloxy-3,11-dihydroxy-4,8,10,14-tetramethyl-2,3,4,5,6,7,9,11,12,13,15,16-dodecahydro-1h-cyclopenta[a]phenanthren-17-ylidene]-6-methylhept-5-enoate Chemical compound [Na+].O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C([O-])=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C HJHVQCXHVMGZNC-JCJNLNMISA-M 0.000 description 1
• 239000007790 solid phase Substances 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 235000010356 sorbitol Nutrition 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 238000010561 standard procedure Methods 0.000 description 1
• 238000007619 statistical method Methods 0.000 description 1
• 239000008117 stearic acid Substances 0.000 description 1
• 210000002784 stomach Anatomy 0.000 description 1
• 239000012089 stop solution Substances 0.000 description 1
• 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
• 229910052717 sulfur Inorganic materials 0.000 description 1
• 239000011593 sulfur Substances 0.000 description 1
• 230000004083 survival effect Effects 0.000 description 1
• 238000001308 synthesis method Methods 0.000 description 1
• 238000003786 synthesis reaction Methods 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 239000007885 tablet disintegrant Substances 0.000 description 1
• 230000008685 targeting Effects 0.000 description 1
• 238000003419 tautomerization reaction Methods 0.000 description 1
• 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
• 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
• 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
• 230000001225 therapeutic effect Effects 0.000 description 1
• 238000002560 therapeutic procedure Methods 0.000 description 1
• 125000001113 thiadiazolyl group Chemical group 0.000 description 1
• 125000004305 thiazinyl group Chemical group S1NC(=CC=C1)* 0.000 description 1
• 125000001984 thiazolidinyl group Chemical group 0.000 description 1
• 125000002769 thiazolinyl group Chemical group 0.000 description 1
• 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
• 238000011200 topical administration Methods 0.000 description 1
• 238000012546 transfer Methods 0.000 description 1
• 230000009466 transformation Effects 0.000 description 1
• 235000013337 tricalcium citrate Nutrition 0.000 description 1
• 229910052722 tritium Inorganic materials 0.000 description 1
• 208000009999 tuberous sclerosis Diseases 0.000 description 1
• 238000002604 ultrasonography Methods 0.000 description 1
• 125000004417 unsaturated alkyl group Chemical group 0.000 description 1
• 230000004218 vascular function Effects 0.000 description 1
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
• 230000009385 viral infection Effects 0.000 description 1
• 230000004580 weight loss Effects 0.000 description 1
• 238000005550 wet granulation Methods 0.000 description 1
• 239000003871 white petrolatum Substances 0.000 description 1
• 239000002023 wood Substances 0.000 description 1
• 229910052725 zinc Inorganic materials 0.000 description 1
• 239000011701 zinc Substances 0.000 description 1